Although there are several target drug have been used in clinical therapy of lung cancer or is in clinical trials, such as EGFR-target TKI (Tyrosine Kinase Inhibitor), ALK-target TKI and VEGF-target Bevacizumab, etc (Fang et al., 2021; Takeyasu et al., 2021; Yu et al., 2021) However, because of the strong heterogeneity, drug resistance and prone to metastasis of lung cancer, the mortality of lung cancer remain high. This evidence concerns the gene ALK and lung carcinoma.